Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia

Shigemura, Katsumi; Yamamichi, Fukashi; Matsumoto, Minori; Tanaka, Kazushi; Yamashita, Masuo; Arakawa, Soichi; Fujisawa, Masato

doi:10.1111/j.1757-5672.2012.00149.x

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tamsulosin, naftopidil, silodosin, terazosin, urapidil and prazosin are approved in Japan, and are apparently of comparable efficacy. The former three have shown ample evidence for efficacy . Postural hypotension and asthenia can occur as rarely as a placebo (4–10%).…”

Section: Treatmentmentioning

confidence: 99%

Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia

et al. 2017

View full text Add to dashboard Cite

The present article is the abbreviated English translation of the Japanese guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia updated as of the end of 2016. The target patients are men aged >50 years complaining of lower urinary tract symptoms, with or without benign prostatic hyperplasia, and the target readers are non-urological general physicians and urologists. Mandatory assessment for general physicians is medical history, physical examination, urinalysis and measurement of serum prostate-specific antigen. Additional mandatory assessment for urologists is symptoms and quality of life assessment by questionnaires, uroflowmetry, residual urine measurement, and prostate ultrasonography. Nocturia requires special attention, as it can result from nocturnal polyuria and/or sleep disturbance rather than lower urinary tract disorders. Functional lower urinary tract disorders with or without benign prostatic hyperplasia are primarily managed by conservative therapy and medications, such as a 1 -blockers and phosphodiesterase-type 5 inhibitors. Use of other medications or combination pharmacotherapy is to be reserved for urologists. 5a-Reductase inhibitors and anticholinergics or b3 agonists are indicated for men with enlarged prostates and overactive bladder symptoms, respectively. Surgical intervention for bladder outlet obstruction is considered for persistent symptoms or benign prostatic hyperplasia-related comorbidities. Surgical modalities should be optimized by the patient's characteristics, performance of equipment and the surgeon's experience.

show abstract

Section: Treatmentmentioning

confidence: 99%

Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia

et al. 2017

View full text Add to dashboard Cite

show abstract

A Review of Naftopidil for Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Fukuta

Masumori

2015

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Comparison of Naftopidil 75 mg with Tamsulosin Hydrochloride 0.2 mg in the Treatment of Lower Urinary Tract Symptoms with Benign Prostatic Hyperplasia

Abstract: Naf 75 mg might show a better efficacy for LUTS with BPH in nocturia frequency than Tam 0.2 mg.

Cited by 2 publications

References 17 publications

Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia

Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia

A Review of Naftopidil for Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Contact Info

Product

Resources

About